Recent studies have shown that oral GLP-1 medications not only reduce appetite but also decrease the pleasure derived from eating by affecting the brain's reward system. This discovery opens up new possibilities for managing eating behavior.
For the first time, the WHO has issued guidelines on the use of GLP-1 drugs for treating obesity, highlighting their effectiveness but also emphasizing their high cost and the need for a comprehensive approach. Experts caution about the lack of long-term studies and stress the importance of prevention.
A new study has shown that semaglutide, a drug used to treat diabetes and obesity, can reduce cocaine cravings in rats. Scientists hope to confirm these results in humans and develop an effective treatment for cocaine addiction.